Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Holding HALO?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.17Last Year’s EPS
$0.82Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -7.14%
|Next Earnings Date:Feb 25, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting record revenue growth, successful new partnerships and approvals, and a positive outlook with increased guidance. A few challenges were noted, particularly around the MDASE platform and product sales fluctuations, but these were outweighed by the positive developments.Company Guidance
During the Halozyme Q3 2024 earnings call, the company provided an optimistic outlook, raising its full-year guidance across several financial metrics. Total revenue for the year is now expected to be between $970 million and $1.02 billion, reflecting a growth of 17% to 23% over 2023, driven by strong performances from key products. Royalty revenues are projected to rise to $550 million to $565 million, showcasing a 23% to 26% increase year over year. Furthermore, adjusted EBITDA is anticipated to grow between 40% and 47%, reaching $595 million to $625 million, while non-GAAP diluted EPS is expected to increase by 44% to 52%, achieving a range of $4 to $4.20. These upward revisions underscore Halozyme's robust growth trajectory and the successful expansion of their enhanced drug delivery technology's adoption.Record Revenue Growth
Halozyme reported a 34% increase in total revenues, reaching an all-time high of $290 million for the third quarter of 2024. Royalty revenue increased by 36% to $155 million.
Positive Outlook and Guidance Increase
Based on strong performance, Halozyme raised its full-year revenue, royalty revenue, adjusted EBITDA, and non-GAAP earnings per share guidance. The company now expects high double-digit revenue growth of 17% to 23% and adjusted EBITDA growth of 40% to 47%.
New Partnerships and Approvals
Two current partners nominated new targets for ENHANZE, and Roche gained two significant regulatory approvals with the FDA. Argenx expanded their agreement with Halozyme, adding four new targets.
Strong Performance of Key Products
DARZALEX sales increased by 23%, Phesgo sales rose by 58%, and VYVGART Hytrulo is expanding in its market. Halozyme's technology is expected to contribute significantly to the revenue growth of these products.
---
HALO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HALO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $50.57 | $57.15 | +13.01% |
| Aug 06, 2024 | $51.94 | $54.12 | +4.20% |
| May 07, 2024 | $41.21 | $42.01 | +1.94% |
| Feb 20, 2024 | $36.00 | $38.36 | +6.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Halozyme Therapeutics (HALO) report earnings?
Halozyme Therapeutics (HALO) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Halozyme Therapeutics (HALO) earnings time?
Halozyme Therapeutics (HALO) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HALO EPS forecast?
HALO EPS forecast for the fiscal quarter 2024 (Q4) is $1.17.
---